SEASONAL AFFECTIVE DISORDER MARKET ANALYSIS BY TYPE, APPLICATION, REGIONS AND COMPANIES FORECAST

  2024-11-27 |   Pages: 200+ |   Report ID: MD-R-2024-11-27-133225 |   Healthcare

Historical data: 2018 - 2023

Forecast period: 2024 - 2031

Quantitative units: Revenue in USD million and CAGR from 2024 to 2031

Report coverage: Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Seasonal Affective Disorder Market

Image

1.1 SCOPE OF THE REPORT

1.2 MARKET SEGMENT ANALYSIS

1.3 REGULATORY SCENARIO BY REGION/COUNTRY

1.4 MARKET INVESTMENT SCENARIO STRATEGIC

1.5 MARKET ANALYSIS BY TYPE (USD MILLION)

1.6 MARKET ANALYSIS BY APPLICATION (USD MILLION)

2.1 DRIVER, RESTRAINT, CHALLENGE AND OPPORTUNITIES ANALYSIS

  2.1.1 MARKET DRIVER ANALYSIS

  2.1.2 MARKET RESTRAINT ANALYSIS

  2.1.3 MARKET OPPORTUNITY

  2.1.4 MARKET CHALLENGES

3.1 INDUSTRY TRENDS

  3.1.1 SWOT ANALYSIS

  3.1.2 PESTEL ANALYSIS

  3.1.3 PORTER’S FIVE FORCES ANALYSIS

3.2 POTENTIAL MARKET AND GROWTH POTENTIAL ANALYSIS

4.1 COVID-19 ANALYSIS

5.1 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET, SALES AREA, TYPE

5.2 MERGERS & ACQUISITIONS, PARTNERSHIPS, PRODUCT LAUNCH, AND COLLABORATION IN GLOBAL SEASONAL AFFECTIVE DISORDER MARKET

7.1 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE (2018-2031) (USD MILLION)

8.1 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

8.2 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

9.1 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

9.2 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

10.1 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY REGION (2018-2023) (USD MILLION)

10.2 GLOBAL SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY REGION (2024-2031) (USD MILLION)

11.1 NORTH AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

11.2 NORTH AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

11.3 NORTH AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

11.4 NORTH AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

11.5 NORTH AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

11.6 NORTH AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

12.1 EUROPE SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

12.2 EUROPE SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

12.3 EUROPE SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

12.4 EUROPE SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

12.5 EUROPE SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

12.6 EUROPE SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

13.1 ASIA PACIFIC SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

13.2 ASIA PACIFIC SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

13.3 ASIA PACIFIC SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

13.4 ASIA PACIFIC SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

13.5 ASIA PACIFIC SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

13.6 ASIA PACIFIC SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

14.1 LATIN AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)/p>

14.2 LATIN AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

14.3 LATIN AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

14.4 LATIN AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

14.5 LATIN AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

14.6 LATIN AMERICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031) (USD MILLION)

15.1 MIDDLE EAST & AFRICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2018-2023) (USD MILLION)

15.2 MIDDLE EAST & AFRICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY COUNTRY (2024-2031) (USD MILLION)

15.3 MIDDLE EAST & AFRICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2018-2023) (USD MILLION)

15.4 MIDDLE EAST & AFRICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY TYPE (2024-2031) (USD MILLION)

15.5 MIDDLE EAST & AFRICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2018-2023) (USD MILLION)

15.6 MIDDLE EAST & AFRICA SEASONAL AFFECTIVE DISORDER MARKET SIZE AND SHARE BY APPLICATION (2024-2031)< (USD MILLION)/p>

16.1 AbbVie Inc. (US)

  16.1.1 COMPANY DETAILS

  16.1.2 FINANCIALS (USD MILLION)

  16.1.3 PRODUCT SUMMARY

  16.1.4 RECENT DEVELOPMENTS

16.2 Allergan (Republic of Ireland)

16.3 Bayer AG (Germany)

16.4 Bristol-Myers Squibb Company (US)

16.5 F. Hoffmann-La Roche Ltd. (Switzerland)

16.6 Henry Schein Inc. (US)

16.7 Pfizer Inc. (US)

18.1 METHODOLOGY

18.2 RESEARCH DATA SOURCE

  18.2.1 SECONDARY DATA

  18.2.2 KEY DATA FROM SECONDARY

  18.2.3 PRIMARY DATA

  18.2.4 KEY DATA FROM PRIMARY

  18.2.5 INDUSTRY INSIGHT FROM PROFESSIONAL LEADERS

  18.2.6 MARKET ESTIMATION

  18.2.7 MARKET ESTIMATION: TOP-DOWN AND BOTTOM-UP APPROACH

  18.2.8 LEGAL DISCLAIMER

Market Segments

By Type

Fall and winter SAD
Spring and summer SAD
Others

By Diagnosis

Physical Exam
Lab Tests
Complete Blood Count (CBC)
Thyroid Blood Tests
Others
Psychological Evaluation
Intelligence Tests
Personality Tests
Attitude Tests
Achievement Tests
Neuropsychological Tests
Vocational Tests
Direct Observation Tests
Others
Others

By Treatment

Light Therapy (Phototherapy)
Bright Light Treatment
Dawn Simulation
Others
Medications
Antidepressants
Reuptake Inhibitors (SSRIs)
Paroxetine (Paxil)
Sertraline (Zoloft)
Bupropion (Wellbutrin)
Venlafaxine (Effexor)
Others
Others
Psychotherapy
Art Therapy
Attachment-Based Psychotherapy
Behavioral Therapy
Body Psychotherapy
Cognitive Analytical Therapy (CAT)
Existential Psychotherapy
Gestalt Therapy
Others
Counselling
Others

By End User

Hospital and Clinics
Academic Institutions
Medical Research Centers
Others

Companies

AbbVie Inc. (US)
Allergan (Republic of Ireland)
Bayer AG (Germany)
Bristol-Myers Squibb Company (US)
F. Hoffmann-La Roche Ltd. (Switzerland)
Henry Schein Inc. (US)
Pfizer Inc. (US)

Single User License  : 3900$
Corporate License    : 7800$
Enquiry Before Buying
Request For Customization
Speak To Analyst

BROWSE INDUSTRY

  1. Consumer Goods
  2. Healthcare
  3. Food & Beverage
  4. Heavy Industry
  5. Service Industries
  6. FMCG
  7. Life Sciences
  8. Technology & Media
  9. Machinery & Equipment

    WHY CHOOSE US

  •   PROACTIVE

    • We manage our resources 24/7 to identify issues and address them before they become problems.

  •   QUALITY & RELIABILITY

    • We are committed to providing reliable and highly accurate data with an excellent quality control system.

  •   GLOBAL OUTREACH

    • 6 Major regions and 40+ countries level analysis accomplished.

  •   COMPETITIVE PRICING

    • Our pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery.